Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 22;14(1):72.
doi: 10.1186/s13071-021-04583-y.

Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar

Benjamin F R Dickson  1 , Patricia M Graves  2   3 , Ni Ni Aye  4 , Thet Wai Nwe  4 , Tint Wai  5 , San San Win  6 , Myint Shwe  7 , Janet Douglass  2   3 , Peter Wood  2 , Kinley Wangdi  8 , William J McBride  9
Affiliations

Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar

Benjamin F R Dickson et al. Parasit Vectors. .

Abstract

Background: Myanmar commenced a lymphatic filariasis (LF) elimination programme in 2000. Whilst the country has made considerable progress since then, a number of districts have demonstrated persistent transmission after many rounds of mass drug administration (MDA). The causes of unsuccessful MDA have been examined elsewhere; however, there remains little information on the factors that contribute in Myanmar.

Methods: We conducted an analysis of factors associated with persistent infection, LF-related hydrocoele and MDA participation in an area with ongoing transmission in 2015. A cross-sectional household survey was undertaken in 24 villages across four townships of Mandalay Region. Participants were screened for circulating filarial antigen (CFA) using immunochromatographic tests and, if positive, for microfilaria by night-time thick blood slide. Individuals 15 year and older were assessed for filariasis morbidity (lymphoedema and, if male, hydrocoele) by ultrasound-assisted clinical examination. A pre-coded questionnaire was used to assess risk factors for LF and for non-participation (never taking MDA). Significant variables identified in univariate analyses were included in separate step-wise multivariate logistic regressions for each outcome.

Results: After adjustment for covariates and survey design, being CFA positive was significantly associated with age [odds ratio (OR) 1.03, 95% CI 1.01-1.06), per year], male gender (OR 3.14, 1.27-7.76), elevation (OR 0.96, 0.94-0.99, per metre) and the density of people per household room (OR 1.59, 1.31-1.92). LF-related hydrocoele was associated with age (OR 1.06, 1.03-1.09, per year) and residing in Amarapura Township (OR 8.93, 1.37-58.32). Never taking MDA was associated with male gender [OR 6.89 (2.13-22.28)] and age, particularly in females, with a significant interaction term. Overall, compared to those aged 30-44 years, the proportion never taking MDA was higher in all age groups (OR highest in those < 5 years and > 60 years, ranging from 3.37 to 12.82). Never taking MDA was also associated with residing in Amarapura township (OR 2.48, 1.15-5.31), moving to one's current village from another (OR 2.62, 1.12-6.11) and ever having declined medication (OR 11.82, 4.25-32.91). Decreased likelihood of never taking MDA was associated with a higher proportion of household members being present during the last MDA round (OR 0.16, 0.03-0.74) and the number visits by the MDA programme (OR 0.69, 0.48-1.00).

Conclusions: These results contribute to the understanding of LF and MDA participation-related risk factors and will assist Myanmar to improve its elimination and morbidity management programmes.

Keywords: Asia; Compliance; Coverage; Hydrocoele; Infection; Lymphatic filariasis; Mass drug administration; Myanmar; Participation; Risk factors.

PubMed Disclaimer

Conflict of interest statement

NNA, TWN, TW and SSW were involved in Myanmar’s National LF Elimination Program at the time of the study. MS works as a self-employed private general practitioner in Mandalay. He volunteered his time to assist with data collection during the study.

References

    1. World Health Organization Global programme to eliminate lymphatic filariasis: progress report, 2018. Wkly Epidemiol Rec. 2019;94(41):457–472.
    1. World Health Organization. WHO global programme to eliminate lymphatic filariasis: progress report for 2000–2009 and strategic plan 2010–2020. 2010.
    1. Aye NN, Lin Z, Lon KN, Linn NYY, Nwe TW, Mon KM, et al. Mapping and modelling the impact of mass drug adminstration on filariasis prevalence in Myanmar. Infect Dis Poverty. 2018;7(1):56. doi: 10.1186/s40249-018-0420-9. - DOI - PMC - PubMed
    1. Dickson BF, Graves PM, McBride WJ. Lymphatic filariasis in Mainland Southeast Asia: a systematic review and meta-analysis of prevalence and disease burden. Trop Med Infect Dis. 2017;2(3):32. doi: 10.3390/tropicalmed2030032. - DOI - PMC - PubMed
    1. Win KM, Tripathy JP, Maung TM, Oo T, Thi A, Lon KN, et al. Rapid progress towards elimination of lymphatic filariasis in endemic regions of Myanmar as a result of 16 years of anti-filarial activities (2001–2016) Trop Med Health. 2018;46(1):14. doi: 10.1186/s41182-018-0093-x. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources